FDA Approves First Drug to Treat Tardive Dyskinesia
The Carlat Psychiatry Report, Volume 15, Number 6, June 2017
https://www.thecarlatreport.com/newsletter-issue/tcprv15n6/
Issue Links: Learning Objectives | Editorial Information
Topics: News of Note | Psychopharmacology
Talia Puzantian
Deputy editor, The Carlat Psychiatry Report
Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
The U.S. Food and Drug Administration approved Ingrezza (valbenazine) for the treatment of tardive dyskinesia (TD), a disabling movement disorder that afflicts 10%–20% of people on chronic antipsychotic medication.
You can't view details of this content, please login or buy subscription here